

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS P.O. Box 1450 Alexandria, Vignita 22313-1450 www.uspto.gov

APPLICATION NO.	99/08/2000		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO. 3652	
09/658,699			Birgit Oppmann	DX01042X		
28008	7590	05/19/2003				
DNAX RES			EXAMINER			
LEGAL DEPARTMENT 901 CALIFORNIA AVENUE				DECLOUX	DECLOUX, AMY M	
PALO ALTO, CA 94304				ART UNIT	PAPER NUMBER	
				1644	7.0	
			•	DATE MAILED: 05/19/2003	Œ	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
		09/658,699	OPPMANN ET AL.				
	Office Action Summary	Examiner	Art Unit				
		Amy M. DeCloux	1644				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status							
1) 🛛	Responsive to communication(s) filed on 27 f	ebruary 2003 .					
2a)⊠	This action is FINAL . 2b) ☐ Th	is action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims							
4) Claim(s) 51-62 is/are pending in the application.							
4a) Of the above claim(s) <u>59-62</u> is/are withdrawn from consideration.							
5)[5) Claim(s) is/are allowed.						
6)⊠	6)⊠ Claim(s) <u>51-58</u> is/are rejected.						
7)	7) Claim(s) is/are objected to.						
	Claim(s) are subject to restriction and/o	r election requirement.					
Application Papers							
9) The specification is objected to by the Examiner.							
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a)[a) All b) Some * c) None of:						
	1. Certified copies of the priority document	s have been received.					
	2. Certified copies of the priority documents have been received in Application No						
 Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) ☐ The translation of the foreign language provisional application has been received.							
15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)							
2) Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s) _	5) Notice of Informa	ary (PTO-413) Paper No(s) al Patent Application (PTO-152)				
J.S. Patent and Tra PTO-326 (Rev		ction Summary	Part of Paper No. 20				

Application/Control Number: 09/658,699

Art Unit: 1644

DETAILED ACTION

Applicant's amendment filed 2-27-03 is acknowledged and has been entered.

In view of said amendment the 112 first and second paragraph rejections have been withdrawn.

However, a new ground of rejection has been applied.

New Ground of Rejection

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 51-58 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Claims 51-58 are not supported by the specification or by the claims as originally filed. There is no support in the specification or claims as originally filed for the recitation of an antibody "wherein said antibody exhibits less than 10% cross reactivity with any epitope presented by IL-B30 alone or p40 alone". There is no written description of the claimed invention in the specification or claims as originally filed. Thus the claimed invention constitutes new matter.

Applicant points to support for said phrase to page 16, lines 15-23 of the specification. The examiner notes that lines 20-23 of said page 16 discloses that antisera with less than 10% crossreactivity with each of the proteins listed above are selected in pooled, and that lines 4-7 of said page disclose that polyclonal antisera with a titer of 10⁴ or greater are selected and tested for their crossreactivity against other closely related family members, e.g. LIF, CT-1, CNTF, or other members of the IL-6 family, using a competitive binding immunoassay such as the one described in Harlow and Lane. The examiner also notes that the recitation of the instant claims of an antibody "wherein said antibody exhibits less than 10% cross reactivity with any epitope presented by IL-B30 alone or p40 alone" is not supported by said page 16 because said page does not disclose an antibody that exhibits less than 10% cross reactivity with any epitope

Art Unit: 1644

presented by IL-B30 alone or p40 alone. Applicant is invited to point out support for said recited phrase.

Conclusion

No Claim is allowed.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

This application contains claims 59-62 drawn to an invention nonelected with traverse in Paper No. 16, filed 9-18-02. A complete reply to the final rejection must include cancellation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Amy M. DeCloux whose telephone number is 703 306-5821. The examiner can normally be reached on M-F 9:00-5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on 703 308-3973. The fax phone numbers for the organization where this application or proceeding is assigned are 703 872-9306 for regular communications and 703 872-9307 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703 308-0196.

Amy DeCloux, Ph.D. Patent Examiner May 7, 2003 Patrick J. Nolan, Ph.D. Primary Patent Examiner Group 1640

Pater 1 MZ